Literature DB >> 33489356

Long-Term Risk of Progression to Sustained Hypertension in White-Coat Hypertension with Normal Night-Time Blood Pressure Values.

João Faria1, José Mesquita Bastos2, Susana Bertoquini3, José Silva3, Jorge Polónia1.   

Abstract

BACKGROUND: The long-term prognosis and transition towards sustained ambulatory hypertension (SHT) of white-coat hypertension (WCHT) remain uncertain particularly in those with both normal nighttime and daytime blood pressure (BP) values. Different classification criteria and the use of antihypertensive drugs may contribute to conflicting results. Patients and Methods. We prospectively evaluated for a 7.1 year transition to SHT in 899 nondiabetic subjects free from cardiovascular (CV) events: normotensive (NT) (n = 344; 52, 9% female; ageing 48 ± 14 years); untreated WCHT (UnWCHT n = 399; 50, 1% female; ageing 51 ± 14 years); and treated WCHT with antihypertensive drugs after baseline (TxWCHT n = 156; 54, 4% female; ageing 51 ± 15 years). All underwent 24 h ambulatory BP monitoring (24 h-ABPM) at baseline, at 30 to 60 months, and at 70 to 120 months thereafter. WCHT was at baseline (with no treatment) as office BP ≥ 140/or 90 mm·Hg, daytime BP < 135/85 mm·Hg, and nighttime BP < 120/70 mm·Hg. Development of SHT was considered if daytime BP ≥ 135/or 85 mm Hg and/or nighttime BP ≥ 120/or 70 mm·Hg.
RESULTS: Baseline metabolic parameters did not differ among groups. At 30-60 months and at the end of follow-up, development of SHT occurred, respectively, in NT (3.8% (n = 13) and 9.6% (n = 33)) and in UnWCHT (10.1% (n = 40) and 16.5% (n = 66)) (p < 0.009). The mean annual increase of average 24 h-systolic BP was 0.48 + 0.93 in NT and 0.73 + 1.06 in UnWCHT, whereas annual SBP in office increased in NT by 1.2 + 0.95 but decreased in UnWCHT by 1.36 + 1.35 mm Hg (p < 0.01).
CONCLUSION: Untreated WCHT patients exhibit a faster and a higher risk of developing SHT compared to NT with TxWCHT assuming an intermediate position between them.
Copyright © 2020 João Faria et al.

Entities:  

Year:  2020        PMID: 33489356      PMCID: PMC7803260          DOI: 10.1155/2020/8817544

Source DB:  PubMed          Journal:  Int J Hypertens            Impact factor:   2.420


  39 in total

Review 1.  Predictive role of the nighttime blood pressure.

Authors:  Tine W Hansen; Yan Li; José Boggia; Lutgarde Thijs; Tom Richart; Jan A Staessen
Journal:  Hypertension       Date:  2010-11-15       Impact factor: 10.190

2.  Long-term risk of sustained hypertension in white-coat or masked hypertension.

Authors:  Giuseppe Mancia; Michele Bombelli; Rita Facchetti; Fabiana Madotto; Fosca Quarti-Trevano; Hernan Polo Friz; Guido Grassi; Roberto Sega
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

3.  2018 ESC/ESH Guidelines for the management of arterial hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  Eur Heart J       Date:  2018-09-01       Impact factor: 29.983

Review 4.  White Coat Hypertension and Cardiovascular Diseases: Innocent or Guilty.

Authors:  Mehran Abolbashari
Journal:  Curr Cardiol Rep       Date:  2018-03-08       Impact factor: 2.931

5.  Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension.

Authors:  K Kario; K Shimada; J E Schwartz; T Matsuo; S Hoshide; T G Pickering
Journal:  J Am Coll Cardiol       Date:  2001-07       Impact factor: 24.094

6.  Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study.

Authors:  R S Khattar; R Senior; A Lahiri
Journal:  Circulation       Date:  1998-11-03       Impact factor: 29.690

7.  Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome.

Authors:  George S Stergiou; Kei Asayama; Lutgarde Thijs; Anastasios Kollias; Teemu J Niiranen; Atsushi Hozawa; José Boggia; Jouni K Johansson; Takayoshi Ohkubo; Ichiro Tsuji; Antti M Jula; Yutaka Imai; Jan A Staessen
Journal:  Hypertension       Date:  2014-01-13       Impact factor: 10.190

8.  The importance of using 24-hour and nighttime blood pressure for the identification of white coat hypertension: Data from the Jackson Heart Study.

Authors:  D Edmund Anstey; Lisandro D Colantonio; Yuichiro Yano; John N Booth Iii; Paul Muntner
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-07-06       Impact factor: 3.738

Review 9.  White-coat hypertension is a risk factor for cardiovascular diseases and total mortality.

Authors:  Yuli Huang; Weijun Huang; Weiyi Mai; Xiaoyan Cai; Dongqi An; Zhuheng Liu; He Huang; Jianping Zeng; Yunzhao Hu; Dingli Xu
Journal:  J Hypertens       Date:  2017-04       Impact factor: 4.844

10.  Prevalence and clinical outcomes of white-coat and masked hypertension: Analysis of a large ambulatory blood pressure database.

Authors:  Giuliano Tocci; Vivianne Presta; Ilaria Figliuzzi; Nadia Attalla El Halabieh; Allegra Battistoni; Roberta Coluccia; Michela D'Agostino; Andrea Ferrucci; Massimo Volpe
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-01-25       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.